Fluorescent antibody titer
CPT code 86256 is used when a laboratory performs a fluorescent antibody titer test, which measures the concentration of specific antibodies in blood using fluorescent dyes to detect immune responses to infections or autoimmune conditions.
This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.
RVU breakdown
Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High
NCCI bundling edits
Loading bundling edits…
Billing tips
Always specify the exact antibody tested in documentation (e.g., ANA, anti-dsDNA, viral-specific antibodies) as 86256 is non-specific and payers may require additional information
Impact: Reduces denial rate by 30-40% by establishing medical necessity upfront
Link appropriate ICD-10 diagnosis codes that justify the specific antibody titer ordered (e.g., suspected infection codes, autoimmune disorder screening codes)
Impact: Medical necessity denials decrease significantly with proper diagnosis linkage; can prevent $17.14 writeoff per test
When billing multiple antibody titers on the same date, use modifier 59 or XU on subsequent line items and ensure documentation supports distinct medical necessity for each
Impact: Allows full reimbursement of $17.14 per titer rather than bundling denial resulting in zero payment for additional tests
Verify LCD (Local Coverage Determination) policies for your MAC regarding frequency limitations and specific antibodies covered under 86256
Impact: Some MACs limit frequency to once per 90 days or specify which antibodies require alternative codes, preventing denials
For reference laboratory testing, ensure proper use of modifier 90 and verify the reference lab's CLIA certification is current and on file
Impact: Incorrect modifier usage can result in full denial or significant payment reduction if technical component is incorrectly billed
Document the clinical necessity for titer quantification rather than qualitative testing, as some payers may question why the more expensive quantitative test is required
Prevents downcoding to qualitative antibody tests which reimburse at lower rates
Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.
Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.
Help build the field knowledge
MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.